Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $11.77 Consensus Target Price from Analysts

by · The Cerbat Gem

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $11.7692.

Several research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. LADENBURG THALM/SH SH initiated coverage on shares of Compass Therapeutics in a report on Wednesday, July 1st. They issued a “buy” rating and a $5.00 price objective on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. Piper Sandler upped their price objective on Compass Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, Stifel Nicolaus set a $6.00 target price on Compass Therapeutics in a research note on Monday, June 1st.

Check Out Our Latest Stock Report on CMPX

Compass Therapeutics Stock Down 2.4%

Compass Therapeutics stock opened at $2.00 on Wednesday. The stock has a 50-day simple moving average of $2.21 and a 200 day simple moving average of $3.17. The stock has a market capitalization of $360.18 million, a price-to-earnings ratio of -5.00 and a beta of 0.95. Compass Therapeutics has a 12-month low of $1.61 and a 12-month high of $6.88.

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, sell-side analysts anticipate that Compass Therapeutics will post -0.47 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Several large investors have recently modified their holdings of CMPX. Palo Alto Investors LP bought a new stake in Compass Therapeutics during the 2nd quarter worth approximately $12,771,670. BlackRock Inc. acquired a new position in shares of Compass Therapeutics in the second quarter valued at approximately $24,707,000. Bank of America Corp DE boosted its holdings in shares of Compass Therapeutics by 224.9% in the first quarter. Bank of America Corp DE now owns 865,613 shares of the company’s stock valued at $4,579,000 after buying an additional 599,179 shares during the period. Royce & Associates LP bought a new stake in shares of Compass Therapeutics during the fourth quarter worth $1,536,000. Finally, Seven Fleet Capital Management LP bought a new stake in shares of Compass Therapeutics during the fourth quarter worth $3,054,000. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

(Get Free Report)

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.

Featured Articles